• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Healthopioid epidemic

Drug Overdose Deaths Fell for the First Time in Three Decades—Opioids Included. Here’s Why

By
Mike Stobbe
Mike Stobbe
and
The Associated Press
Down Arrow Button Icon
August 6, 2019, 5:21 PM ET

Prescriptions of the overdose-reversing drug naloxone are soaring, and experts say that could be a reason overdose deaths have stopped rising for the first time in nearly three decades.

The number of naloxone prescriptions dispensed by U.S. retail pharmacies doubled from 2017 to last year, rising from 271,000 to 557,000, health officials reported Tuesday.

The United States is in the midst of the deadliest drug overdose epidemic in its history. About 68,000 people died of overdoses last year, according to preliminary government statistics reported last month, a drop from the more than 70,000 in 2017.

“One could only hope that this extraordinary increase in prescribing of naloxone is contributing to that stabilization or even decline of the crisis,” said Katherine Keyes, a Columbia University drug abuse expert.

About two-thirds of U.S. overdose deaths involve some kind of opioid, a class of drugs that includes heroin, certain prescription painkillers and illicit fentanyl. Naloxone is a medication that can reverse opioid overdoses, restoring breathing and bringing someone back to consciousness. It first went on sale in 1971 as an injection. An easier-to-use nasal spray version, Narcan, was approved in 2015.

Local, state, and federal officials have embraced naloxone as a lifesaving measure. Cities and states have standing orders that allow pharmacies to give it out without a doctor’s prescription, and officials have tried to put it into the hands of virtually anyone who might encounter a person overdosing, including drug users, police, and even librarians.

CDC researchers noted there were fewer than 1,300 naloxone prescriptions dispensed in 2012, meaning the number grew more than 430-fold in six years.

Health officials said pharmacies should be giving out even more.

“We don’t think anybody is at the level we’d like to see them,” said Dr. Anne Schuchat of the Centers for Disease Control and Prevention.

The CDC report is based on data from IQVIA, a company that tracks health care information, and looked at prescriptions from more than 50,000 retail pharmacies across the country. It included both prescriptions written by doctors for specific patients and those filled under the broader standing orders.

The report offers only a partial picture, however, since only about 20% of naloxone was sold to retail pharmacies in 2017, according to an earlier government report.

Still, it’s the CDC’s first close look at where most retail dispensing is happening. The agency provided data for about 2,900 of the nation’s 3,100 counties and parishes.

The researchers found it was most common in cities, and in the South.

Experts said the findings likely reflect a number of factors. More naloxone is likely prescribed in places where more people are using opioids and where policies increase access.

Of the 30 counties with the highest rate of naloxone dispensing in 2018, 13 were in Virginia and five were in Kentucky. But the highest naloxone dispensing rate was in Marshall County, Ind., according to the CDC data.

The CDC recommends that naloxone be prescribed to patients who are getting high-dose opioids and are at risk for an overdose. It noted that only one naloxone prescription is written for every 69 high-dose opioid prescriptions.

Another finding: The number of high-dose opioid prescription painkillers dispensed fell to about 38 million last year, from nearly 49 million the year before.

That likely also contributed to the decline in overdose deaths last year, Schuchat said.

More must-read stories from Fortune:

—How the maker of the world’s bestselling drug keep prices sky-high

—As the opioid crisis grew, manufacturers supplied and doctors prescribed stronger pills

—Trump administration to allow Americans to get cheaper drugs from Canada

—Why Heineken and Budweiser are killing it with zero-alcohol beer

—Listen to our audio briefing, Fortune 500 Daily

Follow Fortune on Flipboard to stay up-to-date on the latest news and analysis.

About the Authors
By Mike Stobbe
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Success
'I had to take 60 meetings': Jeff Bezos says 'the hardest thing I've ever done' was raising the first million dollars of seed capital for Amazon
By Dave SmithDecember 15, 2025
1 day ago
placeholder alt text
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action, by blocking his calendar every afternoon from Wednesday to Friday 
By Preston ForeDecember 15, 2025
1 day ago
placeholder alt text
Success
Bad luck, six-figure earners: Elon Musk warns that money will 'disappear' in the future as AI makes work (and salaries) irrelevant
By Orianna Rosa RoyleDecember 15, 2025
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, December 15, 2025
By Joseph HostetlerDecember 15, 2025
1 day ago
placeholder alt text
AI
Deloitte's CTO on a stunning AI transformation stat: Companies are spending 93% on tech and only 7% on people
By Nick LichtenbergDecember 15, 2025
1 day ago
placeholder alt text
North America
Ford writes down $19.5 billion as it pivots electric Lighting line of vehicles
By Sasha RogelbergDecember 15, 2025
20 hours ago

Latest in Health

FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
18 hours ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
2 days ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
2 days ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
3 days ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
3 days ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
3 days ago